Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 48,510 matching trials from the live ClinicalTrials.gov search.
Withdrawn Not applicable Interventional Accepts healthy volunteers

Improving Survivorship Among Minority Cancer Dyads

NCT04685551
Conditions
Cancer, Breast Cancer, Colon Cancer, Caregiver Burnout, Lung Cancer
Interventions
Change in knowledge, motivation, skills, and resources
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndrome
Interventions
Nicotinamide Riboside, Pterostilbene
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Completed Not applicable Interventional Results available

Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy

NCT01074229
Conditions
Postoperative Pain
Interventions
Placebo, Drug .5% Ropivacaine, 20 cc of 0.25% ropivacaine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Completed Not applicable Interventional Results available

Testing the Effectiveness of a Falls Prevention System

NCT03678402
Conditions
High Risk for Falling
Interventions
PUP™ sock
Device
Lead sponsor
Tammy Moore
Other
Eligibility
18 Years and older
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Breast Cancer
Interventions
allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Recruiting Phase 4 Interventional

The STOP-MED CTRCD Trial

NCT06183437
Conditions
Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
Interventions
Stopping Heart Failure Medication(s)
Other
Lead sponsor
Dinesh Thavendiranathan
Other
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Conditions
Non-Small-Cell Lung
Interventions
Canakinumab, Docetaxel, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 3 more
Conditions
Adolescent and Young Adult Cancers
Interventions
CyberCycling, Stretching, Resistance Bands
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
15 Years to 30 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Osteo Arthritis Knee
Interventions
active tDCS paired with active MBM, sham tDCS paired with active MBM, active tDCS paired with sham MBM, sham tDCS paired with sham MBM
Device
Lead sponsor
University of Arizona
Other
Eligibility
50 Years to 85 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Lymphoma
Interventions
doxorubicin hydrochloride, vinblastine, standard subtotal nodal irradiation
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
16 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2014
U.S. locations
22
States / cities
La Jolla, California • Wilmington, Delaware • Washington D.C., District of Columbia + 18 more
Conditions
Diabetes Mellitus, Type 2, Prediabetic State, Sleep Initiation and Maintenance Disorders
Interventions
SHUTi, Patient Education
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
22 Years to 79 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Biliary Stricture
Interventions
Temperature-sensitive radiofrequency ablation, No intervention
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Neoplasms, Malignant Carcinoma
Interventions
Neratinib, Temsirolimus
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Results available

Youth Mayo Clinic Anxiety Coach Pilot Study

NCT02205177
Conditions
Anxiety
Interventions
Mayo Clinic Anxiety Coach
Device
Lead sponsor
Stephen Whiteside
Other
Eligibility
7 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
HIV Infections
Interventions
DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine, Placebo for DNA-HIV-PT123 vaccine, Placebo for NYVAC-HIV-PT1 vaccine, Placebo for NYVAC-HIV-PT4 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO), Guanfacine (GFC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
17,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Titusville, New Jersey
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Other Cancer
Interventions
Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application, Digital application with expert guidelines on lifestyle modification
Behavioral
Lead sponsor
Complement Theory Inc.
Industry
Eligibility
21 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dover, Delaware
Conditions
Colorectal Cancer
Interventions
bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin
Biological · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Unresectable Urothelial Carcinoma
Interventions
Bevacizumab, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
872
States / cities
Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 529 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
56
States / cities
Tucson, Arizona • Anaheim, California • Canoga Park, California + 46 more
Conditions
Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial
Interventions
7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment.
Other
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years and older
Enrollment
3,622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Conditions
Hepatitis C
Interventions
200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD, Placebo QD, 100 mg INX-08189 with low-fat meal, Placebo with low-fat meal, 100 mg INX-08189 BID Fasted, Placebo BID Fasted, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Hypercholesterolemia, Familial
Interventions
ISIS 301012
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 2 more
Conditions
Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation
Interventions
TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab
Drug
Lead sponsor
Tempest Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Aurora, Colorado • Baltimore, Maryland • Springfield, Massachusetts + 8 more